K. Nicholson, J. Kent, V. Hammersley, and E. Cancio, Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden, BMJ, vol.315, issue.7115, pp.1060-1064, 1997.
DOI : 10.1136/bmj.315.7115.1060

M. Zambon, J. Hays, A. Webster, R. Newman, and O. Keene, Diagnosis of Influenza in the Community, Archives of Internal Medicine, vol.161, issue.17, pp.2116-2138, 2001.
DOI : 10.1001/archinte.161.17.2116

J. Ellis, D. Fleming, and M. Zambon, Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996, J Clin Microbiol, vol.35, issue.8, pp.2076-82, 1997.

D. Fleming, P. Chakraverty, C. Sadler, and P. Litton, Combined clinical and virological surveillance of influenza in winters of 1992 and 1993-4, BMJ, vol.311, issue.7000, pp.290-291, 1995.
DOI : 10.1136/bmj.311.7000.290

A. Monto, S. Ohmit, J. Margulies, and A. Talsma, Medical Practice-based Influenza Surveillance: Viral Prevalence and Assessment of Morbidity, American Journal of Epidemiology, vol.141, issue.6, pp.502-508, 1995.
DOI : 10.1093/oxfordjournals.aje.a117464

F. Carrat, A. Tachet, C. Rouzioux, B. Housset, and A. Valleron, Evaluation of Clinical Case Definitions of Influenza: Detailed Investigation of Patients During the 1995???1996 Epidemic in France, Clinical Infectious Diseases, vol.28, issue.2, pp.283-90, 1999.
DOI : 10.1086/515117

A. Monto, D. Fleming, and D. Henry, Efficacy and Safety of the Neuraminidase Inhibitor Zanamivirin the Treatment of Influenza A and B Virus Infections, The Journal of Infectious Diseases, vol.180, issue.2, pp.254-61, 1999.
DOI : 10.1086/314904

F. Hayden, A. Osterhaus, and J. Treanor, Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections, New England Journal of Medicine, vol.337, issue.13, pp.874-80, 1997.
DOI : 10.1056/NEJM199709253371302

. Mist-study and . Group, Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [published errata appear in, Lancet Lancet, vol.353353, issue.3529144, pp.1877-81, 1998.

J. Treanor, F. Hayden, and P. Vrooman, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza, JAMA, vol.283, issue.8, pp.1016-1040, 2000.
DOI : 10.1001/jama.283.8.1016

K. Nicholson, F. Aoki, and A. Osterhaus, Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, The Lancet, vol.355, issue.9218, pp.1845-5027, 2000.
DOI : 10.1016/S0140-6736(00)02288-1

G. Boivin, N. Goyette, I. Hardy, F. Aoki, A. Wagner et al., Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults, The Journal of Infectious Diseases, vol.181, issue.4, pp.1471-1475, 2000.
DOI : 10.1086/315392

D. Fleming, M. Zambon, and A. Bartelds, Population estimates of persons presenting to general practitioners with influenza-like illness, 1987???96: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands, Epidemiology and Infection, vol.124, issue.2, pp.245-53, 2000.
DOI : 10.1017/S0950268899003660

F. Carrat, C. Sahler, and S. Rogez, Influenza Burden of Illness, Archives of Internal Medicine, vol.162, issue.16, pp.1842-1850, 1998.
DOI : 10.1001/archinte.162.16.1842

R. Couch, Drug Therapy: Prevention and Treatment of Influenza, N Engl J Med, vol.343, issue.24, pp.1778-1787, 2000.

P. Gross, A. Hermogenes, H. Sacks, J. Lau, and R. Levandowski, The Efficacy of Influenza Vaccine in Elderly Persons, Annals of Internal Medicine, vol.123, issue.7, pp.518-545, 1995.
DOI : 10.7326/0003-4819-123-7-199510010-00008

K. Nicholson, Socioeconomics of Influenza and Influenza Vaccination in Europe, PharmacoEconomics, vol.9, issue.Supplement 3, pp.75-83, 1996.
DOI : 10.2165/00019053-199600093-00017

A. Hampson and L. Irving, Influenza vaccination: cost-effective health care for the older adult?, J Qual Clin Pract, vol.17, issue.1, pp.3-11, 1997.

F. Ambrosch and D. Fedson, Influenza Vaccination in 29 Countries, PharmacoEconomics, vol.16, issue.Supplement 1, pp.47-54, 1999.
DOI : 10.2165/00019053-199916001-00007

J. Lalezari, K. Campion, O. Keene, and C. Silagy, Zanamivir for the Treatment of Influenza A and B Infection in High-Risk Patients, Archives of Internal Medicine, vol.161, issue.2, pp.212-219, 2001.
DOI : 10.1001/archinte.161.2.212

S. Gravenstein and H. Davidson, Current Strategies for Management of Influenza in the Elderly Population, Clinical Infectious Diseases, vol.35, issue.6, pp.729-766, 2002.
DOI : 10.1086/341246

T. Jefferson, V. Demicheli, J. Deeks, and D. Rivetti, Neuraminidase inhibitors for preventing and treating influenza in healthy adults, Cochrane Database Syst Rev, vol.2, 2000.

T. Jefferson, V. Demicheli, J. Deeks, and D. Rivetti, Amantadine and rimantadine for preventing and treating influenza A in adults, Cochrane Database Syst Rev, vol.2, 2000.

F. Hayden, L. Gubareva, and A. Monto, Inhaled Zanamivir for the Prevention of Influenza in Families, New England Journal of Medicine, vol.343, issue.18, pp.1282-1289, 2000.
DOI : 10.1056/NEJM200011023431801

R. Welliver, A. Monto, and O. Carewicz, Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.285, issue.6, pp.748-54, 2001.
DOI : 10.1001/jama.285.6.748

P. Scuffham and P. West, * showcase of economic evaluation of NA-inhibitors 29 Economic evaluation of strategies for the control and management of influenza in Europe, Vaccine, vol.201920, pp.2562-78, 2002.

K. Nichol, A. Lind, and K. Margolis, The Effectiveness of Vaccination against Influenza in Healthy, Working Adults, New England Journal of Medicine, vol.333, issue.14, pp.889-93, 1995.
DOI : 10.1056/NEJM199510053331401

K. Nichol, Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults, Vaccine, vol.17, pp.67-73, 1999.
DOI : 10.1016/S0264-410X(99)00110-3

C. Bridges, W. Thompson, and M. Meltzer, Effectiveness and Cost-Benefit of Influenza Vaccination of Healthy Working Adults, JAMA, vol.284, issue.13, pp.1655-63, 2000.
DOI : 10.1001/jama.284.13.1655

K. Nichol, Cost-Benefit Analysis of a Strategy to Vaccinate Healthy Working Adults Against Influenza, Archives of Internal Medicine, vol.161, issue.5, pp.749-59, 2001.
DOI : 10.1001/archinte.161.5.749

P. Lee, D. Matchar, D. Clements, J. Huber, J. Hamilton et al., Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults, Annals of Internal Medicine, vol.137, issue.4, pp.225-256, 2002.
DOI : 10.7326/0003-4819-137-4-200208200-00005

L. Gubareva, L. Kaiser, and F. Hayden, Influenza virus neuraminidase inhibitors, The Lancet, vol.355, issue.9206, pp.827-862, 2000.
DOI : 10.1016/S0140-6736(99)11433-8

S. Bantia, C. Parker, and S. Ananth, Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir, Antimicrobial Agents and Chemotherapy, vol.45, issue.4, pp.1162-729, 2001.
DOI : 10.1128/AAC.45.4.1162-1167.2001

E. Govorkova, I. Leneva, O. Goloubeva, K. Bush, and R. Webster, Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses, Antimicrobial Agents and Chemotherapy, vol.45, issue.10, pp.2723-2755, 2001.
DOI : 10.1128/AAC.45.10.2723-2732.2001

L. Gubareva, R. Webster, and F. Hayden, Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants, Antimicrobial Agents and Chemotherapy, vol.45, issue.12, pp.3403-3411, 2001.
DOI : 10.1128/AAC.45.12.3403-3408.2001

G. Boivin and N. Goyette, Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors, Antiviral Research, vol.54, issue.3, pp.143-150, 2002.
DOI : 10.1016/S0166-3542(01)00219-4

A. Burls, W. Clark, and T. Stewart, Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation, Health Technology Assessment, vol.6, issue.9, pp.1-87, 2002.
DOI : 10.3310/hta6090

F. Hayden, J. Treanor, and R. Fritz, Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza, JAMA, vol.282, issue.13, pp.1240-1246, 1999.
DOI : 10.1001/jama.282.13.1240

J. Williamson and P. Pegram, Respiratory Distress Associated with Zanamivir, New England Journal of Medicine, vol.342, issue.9, pp.661-663, 2000.
DOI : 10.1056/NEJM200003023420914

P. Diggory, C. Fernandez, A. Humphrey, V. Jones, and M. Murphy, Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled, BMJ, vol.322, issue.7286, pp.577-586, 2001.
DOI : 10.1136/bmj.322.7286.577

L. Gubareva, R. Webster, and F. Hayden, Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay, Antiviral Research, vol.53, issue.1, pp.47-61, 2002.
DOI : 10.1016/S0166-3542(01)00192-9

S. Ph, D. Archard, M. Mcdaid, and D. , Searching literature databases for health care economic evaluations: how systematic can we afford to be?, Med Care, vol.40, issue.5, pp.387-94, 2002.

J. Mauskopf, S. Cates, A. Griffin, D. Neighbors, S. Lamb et al., Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia, PharmacoEconomics, vol.34, issue.14, pp.611-631, 2000.
DOI : 10.2165/00019053-200017060-00007

B. Brady, L. Mcauley, and V. Shukla, Economic evaluation of zanamivir for the treatment of influenza. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2001.

P. Muennig and K. Khan, Cost???Effectiveness of Vaccination versus Treatment of Influenza in Healthy Adolescents and Adults, Clinical Infectious Diseases, vol.33, issue.11, pp.1879-85, 2001.
DOI : 10.1086/324491

K. Smith and M. Roberts, Cost-effectiveness of newer treatment strategies for influenza, The American Journal of Medicine, vol.113, issue.4, pp.300-307, 2002.
DOI : 10.1016/S0002-9343(02)01222-6

M. Housset, B. Carrat, and F. , Rapid flu test and neuraminidase inhibitors in healthy adults : a cost-benefit analysis. In: Options for the control of influenza IV, ADME Osterhaus et al, 2000.

S. Blitz, P. Cram, M. Chernew, A. Monto, and A. Fendrick, Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes, Am J Manag Care, vol.8, issue.3, pp.221-228, 2002.

L. Kaiser, O. Keene, J. Hammond, M. Elliott, and F. Hayden, Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults, Archives of Internal Medicine, vol.160, issue.21, pp.3234-3274, 2000.
DOI : 10.1001/archinte.160.21.3234

F. Aoki, D. Fleming, A. Griffin, L. Lacey, and S. Edmundson, Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza, PharmacoEconomics, vol.295, issue.2, pp.187-95, 2000.
DOI : 10.2165/00019053-200017020-00007

M. Drummond, O. Brien, B. Stoddart, G. Torrance, and G. , Methods for the Economic Evaluation of Health Care Programmes, 1997.

*. Essential, M. Gold, J. Siegel, L. Russell, and M. Weinstein, very well developed text on the willingness-to-pay approach 56 Cost-effectiveness in Health and Medicine, 1996.

W. Brouwer, M. Koopmanschap, and F. Rutten, Productivity losses without absence: measurement validation and empirical evidence, Health Policy, vol.48, issue.1, pp.13-2731, 1999.
DOI : 10.1016/S0168-8510(99)00028-7

A. Monto, S. Gravenstein, M. Elliott, M. Colopy, and J. Schweinle, Clinical Signs and Symptoms Predicting Influenza Infection, Archives of Internal Medicine, vol.160, issue.21, pp.1351-1353, 2000.
DOI : 10.1001/archinte.160.21.3243

K. Neuzil, G. Reed, E. Mitchel, J. Griffin, and M. , Influenza-Associated Morbidity and Mortality in Young and Middle-Aged Women, JAMA, vol.281, issue.10, pp.901-908, 1999.
DOI : 10.1001/jama.281.10.901

S. Jansen, A. Stiggelbout, and P. Wakker, Patients' Utilities for Cancer Treatments: A Study of the Chained Procedure for the Standard Gamble and Time Tradeoff, Medical Decision Making, vol.18, issue.4, pp.391-400, 1998.
DOI : 10.1177/0272989X9801800406

G. Hawthorne and J. Richardson, Measuring the value of program outcomes: a review of multiattribute utility measures, Expert Review of Pharmacoeconomics & Outcomes Research, vol.1, issue.2, pp.215-243, 2001.
DOI : 10.1586/14737167.1.2.215

S. Birch, A. Gafni, and B. O-'brien, Willingness to Pay and the Valuation of Programmes for the Prevention and Control of Influenza, PharmacoEconomics, vol.16, issue.Supplement 1, pp.55-61, 1999.
DOI : 10.2165/00019053-199916001-00008

J. Arana and C. Leon, Willingness to pay for health risk reduction in the context of altruism, Health Economics, vol.23, issue.1, pp.623-658, 2002.
DOI : 10.1002/hec.687

C. Meier, P. Napalkov, Y. Wegmuller, T. Jefferson, and H. Jick, Population-Based Study on Incidence, Risk Factors, Clinical Complications and Drug Utilisation Associated with Influenza in the United Kingdom, European Journal of Clinical Microbiology & Infectious Diseases, vol.19, issue.11, pp.834-876, 2000.
DOI : 10.1007/s100960000376

R. Gonzales, J. Steiner, and M. Sande, Antibiotic Prescribing for Adults With Colds, Upper Respiratory Tract Infections, and Bronchitis by Ambulatory Care Physicians, JAMA: The Journal of the American Medical Association, vol.278, issue.11, pp.901-905, 1997.
DOI : 10.1001/jama.1997.03550110039033

H. Neu, The Crisis in Antibiotic Resistance, Science, vol.257, issue.5073, pp.1064-73, 1992.
DOI : 10.1126/science.257.5073.1064

M. Cohen, Epidemiology of Drug Resistance: Implications for a Post--Antimicrobial Era, Science, vol.257, issue.5073, pp.1050-1055, 1992.
DOI : 10.1126/science.257.5073.1050

R. Gonzales, J. Bartlett, and R. Besser, Principles of Appropriate Antibiotic Use for Treatment of Acute Respiratory Tract Infections in Adults: Background, Specific Aims, and Methods, Annals of Internal Medicine, vol.134, issue.6, pp.479-86, 2001.
DOI : 10.7326/0003-4819-134-6-200103200-00013

R. Gonzales, J. Bartlett, R. Besser, J. Hickner, J. Hoffman et al., Principles of Appropriate Antibiotic Use for Treatment of Nonspecific Upper Respiratory Tract Infections in Adults: Background, Annals of Internal Medicine, vol.134, issue.6, pp.490-494, 2001.
DOI : 10.7326/0003-4819-134-6-200103200-00015

J. Coast, R. Smith, and M. Millar, Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?, Health Economics, vol.5, issue.3, pp.217-2632, 1996.
DOI : 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S

J. Coast, R. Smith, A. Karcher, P. Wilton, and M. Millar, Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?, Health Economics, vol.78, issue.7, pp.637-684, 2002.
DOI : 10.1002/hec.693

G. Chapman and E. Coups, Predictors of Influenza Vaccine Acceptance among Healthy Adults, Preventive Medicine, vol.29, issue.4, pp.249-62, 1999.
DOI : 10.1006/pmed.1999.0535

E. Stone, S. Morton, and M. Hulscher, Interventions That Increase Use of Adult Immunization and Cancer Screening Services, Annals of Internal Medicine, vol.136, issue.9, pp.641-51, 2002.
DOI : 10.7326/0003-4819-136-9-200205070-00006

E. Brass, Changing the status of drugs from prescription to over-the-counter availability